C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. (Q51055322)

27 March 2018

title

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. (English)

1 reference

27 March 2018

Atsushi Sakuraba

2

0 references

Toshifumi Hibi

1

Toshifumi Hibi

1 reference

27 March 2018

Mamoru Watanabe

3

Mamoru Watanabe

1 reference

27 March 2018

Takayuki Matsumoto

12

Takayuki Matsumoto

1 reference

27 March 2018

Takayuki Matsumoto

14

Takayuki Matsumoto

1 reference

27 March 2018

Shinji Tanaka

16

Shinji Tanaka

1 reference

27 March 2018

Toshiyuki Matsui

18

Toshiyuki Matsui

1 reference

27 March 2018

Satoshi Motoya

4

Satoshi Motoya

1 reference

27 March 2018

Masakazu Takazoe

10

Masakazu Takazoe

1 reference

27 March 2018

author name string

Hiroaki Ito

5

1 reference

27 March 2018

Noriko Sato

6

1 reference

27 March 2018

Toru Yoshinari

7

1 reference

27 March 2018

Kenta Motegi

8

1 reference

27 March 2018

Yoshitaka Kinouchi

9

1 reference

27 March 2018

Yasuo Suzuki

11

1 reference

27 March 2018

Kazuhiko Kawakami

13

1 reference

27 March 2018

Ichiro Hirata

15

1 reference

27 March 2018

Toshifumi Ashida

17

1 reference

27 March 2018

publication date

20 April 2013

1 reference

27 March 2018

Journal of Gastroenterology

published in

1 reference

27 March 2018

volume

49

1 reference

27 March 2018

issue

2

1 reference

27 March 2018

page(s)

254-262

1 reference

27 March 2018

The natural history of adult Crohn's disease in population-based cohorts

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Infliximab in the treatment of Crohn's disease: a user's guide for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0807-0

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Plasma IL‐6, plasma VEGF, and serum YKL‐40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I

1 reference

12 December 2020

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease

1 reference

12 December 2020

Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab.

1 reference

12 December 2020

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

12 December 2020

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis

1 reference

12 December 2020

A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease

1 reference

12 December 2020

10.1007/S00535-013-0807-0

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018